NEW YORK (GenomeWeb) – Cell-and bead-based screening technologies firm IntelliCyt has closed a $2.5 million secured term loan agreement and a $1.5 million revolving line of credit from Oxford Finance, the financing firm announced today.

Albuquerque, NM-based IntelliCyt will use the debt facility for working capital, as well as product development and marketing. The company develops high-throughput, high-content screening products for phenotypic drug discovery, antibody discovery, and in vivo toxicity testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.